$1.57
+0.02 (+1.29%)
Open$1.57
Previous Close$1.55
Day High$1.59
Day Low$1.51
52W High$2.59
52W Low$0.70
Volume—
Avg Volume728.0K
Market Cap75.82M
P/E Ratio—
EPS$-0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+2,285.4% upside
Current
$1.57
$1.57
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.41M | 3.79M | 3.81M |
| Net Income | -14,015,166 | 783.4K | 928.9K |
| Profit Margin | -994.5% | 20.7% | 24.4% |
| EBITDA | -15,695,567 | 1.80M | 1.92M |
| Free Cash Flow | — | 820.9K | 949.0K |
| Rev Growth | — | +6.9% | +13.5% |
| Debt/Equity | — | 0.92 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |